Protocol summary

Study aim
Comparison of the length of the bruising period between the intervention and the placebo groups
Design
A parallel double blind on 80 nasolabial filler-injected patients having ecchymosis clinical trial, randomized with blocks of four.
Settings and conduct
After obtaining approval from the ethics committee and obtaining the clinical trial code, the study entered the implementation stage and was carried out at Razi Dermatology Hospital under the supervision of 2 professors of Tehran University of Medical Sciences with the help of a nurse and a statistical consultant.
Participants/Inclusion and exclusion criteria
Inclusion criteria includes receiving nasolabial filler injection at Razi Hospital (having bruises caused by the injection) and entry age is 18 to 65 years old. Exclusion criteria includes pregnancy, breastfeeding, taking aspirin or other anticoagulants. Exiting criteria includes pregnancy (or having plan for pregnancy) and not assigning inform consent.
Intervention groups
-Intervention group (3 times/day for 14 days). -Placebo group (3 times/day for 14 days).
Main outcome variables
Severity of bruising based on surface area The stage (age) of bruises between intervention cream and Placebo at each stage The bruise healing period based on the day of the intervention

General information

Reason for update
Acronym
DABCET-F
IRCT registration information
IRCT registration number: IRCT20141209020250N7
Registration date: 2023-08-19, 1402/05/28
Registration timing: registered_while_recruiting

Last update: 2023-08-19, 1402/05/28
Update count: 0
Registration date
2023-08-19, 1402/05/28
Registrant information
Name
Narges Ghandi
Name of organization / entity
Tehran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 5561 8989
Email address
nghandi@tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-07-23, 1402/05/01
Expected recruitment end date
2023-10-23, 1402/08/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparative Efficacy Evaluation of a Topical Cream (DEMUlcent ™) Containing Arnica and Rosemary Extracts with Placebo on Filler-Injected Patients Bruise: A randomized Double-blind Control Trial
Public title
Evaluation of DEMU La' farrerr Topical Cream Effect on Bruises Caused by Filler Injection
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Individuals Receiving Nasolabial Filler Injection or Facial Botox at Razi Hospital (With Bruises Caused by Filler Injection in the Face Area) Age between 18 and 65
Exclusion criteria:
Pregnancy Possibility or Having Plan for Pregnancy in the Next 3 Months Lactation Taking Aspirin and Other Anticoagulant Medicines Unwillingness to Participating in the Trial
Age
From 18 years old to 65 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
In each of the two intervention groups, the participants are divided into randomized blocks based on the randomization process after confirming that they have the conditions to enter the project. Randomization in this way has been done with the help of 4 random blocks. Each of the houses is A or B, and when the patients go to the hospital, depending on the prepared envelopes, where the patient's number and the type of intervention A or B are marked on each envelope and the type of intervention A or B is marked inside the envelope, from the box containing product A Or it is given from the box containing product B. In this study, 6 types of blocks for each block of 4 can be expected, with two placebo and two intervention volunteers in each group. Each block model is marked with a number from one to six, and for each block, a random number is taken from 1 to 6 with the help of Microsoft Excel, which determines the sequence of receiving cream and placebo for each person, and the total sequence . And the order of 20 blocks of this study is determined.
Blinding (investigator's opinion)
Double blinded
Blinding description
Initially, patients are included in the process of research and are added to the plan if they wish. For more familiarity and assurance, an informed consent form is given to them. After entering the plan and seeing a bruise at the place of filler injection, in the first visit, they will be given an envelope containing the representative number of each person based on the appointment and the number that will be assigned to them. There is a sheet in each of these envelopes, some of which are sheet A and others are sheet B. Depending on which sheet the patient's envelope contains, a cream from box A or a cream from box B will be given from the two boxes available to the nurse of the plan. A double-blind study means that all creams and boxes A or B are blinded for the research doctors of the plan, the executive director, the associate nurse, the patients, and all the hospital staff. Also, the formulation company delivers the intervention cream and placebo in the form of two separate boxes, and the labeling of which cream A contains intervention cream (demo) or placebo and B is done only by and with the knowledge of the plan's statistical consultant. And only he is aware of the grouping, but he does not participate or interfere in the process of implementing the plan. The method of randomization is based on the method that was explained. All the creams with white tube and no explanation except that they are A or B. And in the process of formulating both, all facilities are used by the patient to match the color, smell, consistency, appearance and other tangible characteristics so that the type of cream available in each group A and B is not predictable.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Research Ethics Committees of School of Medicine- Tehran University of Medical Sciences
Street address
Keshavarz Blvd., Corner of Qods St., Central Organization of Tehran University of Medical Sciences, 6th floor: Room 604 (Research and Technology Affairs Experts and Ethics Committee)
City
Tehran
Province
Tehran
Postal code
1417653761
Approval date
2023-08-06, 1402/05/15
Ethics committee reference number
IR.TUMS.MEDICINE.REC.1402.257

Health conditions studied

1

Description of health condition studied
Bruising Caused by Nasolabial Filler Injection
ICD-10 code
R23.3
ICD-10 code description
Spontaneous ecchymoses (Petechiae). Excl: ecchymoses in fetus and newborn, purpura.

Primary outcomes

1

Description
Bruise Intensity by the Surface Area
Timepoint
Days 1, 2, 3, 4, 5, 7, 10 and 14
Method of measurement
Total bruised area measurement

2

Description
The stage (age) of bruises
Timepoint
Days 1, 2, 3, 4, 5, 7, 10 and 14
Method of measurement
Spot Color by Colorimetric Scale NNDV No. 2

3

Description
Bruise Control Time Period
Timepoint
Length of treatment period (14 days)
Method of measurement
Clinical examination and review of images taken from the position

Secondary outcomes

1

Description
Pain feeling in the spot
Timepoint
Days 1, 2, 3, 4, 5, 7, 10 and 14
Method of measurement
The numeric rating scale (NRS)

2

Description
Side Effects (Hypersensitivity or any other side effects not related to other treatments and medicines received by the patient)
Timepoint
Length of treatment period (14 days)
Method of measurement
Patient statements during examinations and other times

3

Description
Volume of filler injected to the site by ml
Timepoint
Day 0 (Filler injection)
Method of measurement
ml of filler injected

Intervention groups

1

Description
Intervention group: DEMUlcent Cream Containing Arnica, Rosemary, Chamomile and... Extracts La' farrerr in a white and unspecified Tube/Used for 14 days, Every 8 Hours at the Filler Injection Site and Around.
Category
Treatment - Drugs

2

Description
Control group: Placebo Cream Containing Other Ingredients Found in DEMUlcent La' farrerr Cream in a White and Unspecified Tube with the Same Smell and Viscosity/Used for 14 days, every 8 hours at the filler injection site and around of it
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Razi Specialty Skin Hospital
Full name of responsible person
Dr.Narges Ghandi
Street address
Razi DdEnd., Vahdate-Eslami St., Vahdate-Eslami Sq., Tehran Town
City
Tehran
Province
Tehran
Postal code
1199663911
Phone
+98 21 5561 8989
Email
nghandi@tums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr.Narges Ghandi
Street address
Razi DdEnd., Vahdate-Eslami St., Vahdate-Eslami Sq., Tehran Town
City
Tehran
Province
Tehran
Postal code
1199663911
Phone
+98 21 5561 8989
Fax
+98 21 5515 5050
Email
nghandi@tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
1
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

2

Sponsor
Name of organization / entity
PergasTeb Ltd.
Full name of responsible person
Dr. Nasim Karimi
Street address
Tehran-Jordan St.-West Saba Blvd.-P.36
City
Tehran
Province
Tehran
Postal code
1917763888
Phone
+98 21 7236 2000
Email
n.karimi@lafarrerr.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
PergasTeb Ltd.
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Danial Mehrali
Position
Pharm.D Student
Latest degree
A Level or less
Other areas of specialty/work
Medical Pharmacy
Street address
Pharmacy Faculty., Tehran University of Medical Sciences., 16 Azar St., Keshavarz Blvd., Tehran
City
Tehran
Province
Tehran
Postal code
1417614411
Phone
+98 21 64120
Email
danielmehrali@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr. Narges Ghandi
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
District 12, vahdate eslami square, Razi hospital
City
Tehran
Province
Tehran
Postal code
1199663911
Phone
+98 21 5563 0553
Email
nghandi@tums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr.Narges Ghandi
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Razi DdEnd., Vahdate-Eslami St., Vahdate-Eslami Sq., Tehran Town
City
Tehran
Province
Tehran
Postal code
1199663911
Phone
+98 21 5561 8989
Fax
+98 21 5515 5050
Email
nghandi@tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
Related information aren't published publicly, but will be available anytime.
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...